Stockscreener 앱 받기
21.64
2.32%
0.49
시간 외 거래:
21.64
전일 마감가:
$21.15
열려 있는:
$21.36
하루 거래량:
3.91M
Relative Volume:
2.46
시가총액:
$1.93B
수익:
$333.87M
순이익/손실:
$-169.00M
주가수익비율:
-10.61
EPS:
-2.04
순현금흐름:
$-157.30M
1주 성능:
+23.66%
1개월 성능:
+29.74%
6개월 성능:
+11.49%
1년 성능:
+117.93%
1일 변동 폭
$21.19
$22.24
1주일 범위
$17.27
$22.24
52주 변동 폭
$10.64
$25.29
Travere Therapeutics Inc Stock (TVTX) Company Profile
명칭
Travere Therapeutics Inc
전화
888-969-7879
주소
3611 VALLEY CENTRE DR, SAN DIEGO
TVTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TVTX
Travere Therapeutics Inc
|
21.64 | 1.89B | 333.87M | -169.00M | -157.30M | -2.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-11 | 재확인 | Citigroup | Buy |
| 2025-06-11 | 재개 | H.C. Wainwright | Buy |
| 2025-01-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-10-21 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-09-09 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2024-03-27 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2023-12-05 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-11-20 | 개시 | Citigroup | Neutral |
| 2023-09-22 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-09-21 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-09-06 | 재개 | Evercore ISI | Outperform |
| 2023-07-21 | 개시 | JP Morgan | Overweight |
| 2023-06-07 | 재개 | Piper Sandler | Neutral |
| 2023-05-22 | 개시 | TD Cowen | Outperform |
| 2023-05-05 | 업그레이드 | Bryan Garnier | Sell → Neutral |
| 2023-03-01 | 개시 | Guggenheim | Buy |
| 2023-02-21 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2022-12-14 | 개시 | Stifel | Hold |
| 2022-12-05 | 개시 | Wells Fargo | Overweight |
| 2022-09-21 | 개시 | Bryan Garnier | Sell |
| 2022-07-14 | 재개 | Canaccord Genuity | Buy |
| 2022-03-31 | 개시 | Piper Sandler | Overweight |
| 2022-02-28 | 개시 | H.C. Wainwright | Buy |
| 2021-05-26 | 다운그레이드 | Wedbush | Outperform → Neutral |
모두보기
Travere Therapeutics Inc 주식(TVTX)의 최신 뉴스
Chart based analysis of Travere Therapeutics Inc. trends2025 Geopolitical Influence & Intraday High Probability Alerts - Newser
Identifying reversal signals in Travere Therapeutics Inc.July 2025 Analyst Calls & Advanced Technical Analysis Signals - Newser
Improved Revenues Required Before Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock's 26% Jump Looks Justified - simplywall.st
Is Travere Therapeutics Inc. a good ESG investmentJuly 2025 Setups & Reliable Intraday Trade Alerts - خودرو بانک
Travere Therapeutics Inc. stock trend forecastWeekly Trade Summary & Weekly Hot Stock Watchlists - Newser
How sensitive is Travere Therapeutics Inc. to inflation2025 Analyst Calls & Daily Entry Point Trade Alerts - خودرو بانک
What is Travere Therapeutics Inc.’s book value per share2025 Market Overview & Smart Swing Trading Techniques - خودرو بانک
Can Travere Therapeutics Inc. lead its sector in growthPortfolio Performance Report & Long-Term Capital Growth Ideas - خودرو بانک
Can Travere Therapeutics Inc. rally from current levels2025 Analyst Calls & Smart Allocation Stock Reports - Newser
Does Travere Therapeutics Inc. stock have upside surprise potentialMarket Growth Review & Fast Entry High Yield Tips - خودرو بانک
Travere Therapeutics Inc. recovery potential after sell offJuly 2025 Action & Fast Momentum Stock Entry Tips - Newser
What is the earnings history of Travere Therapeutics Inc.Price Action & Verified Momentum Watchlists - خودرو بانک
Is Travere Therapeutics Inc. trending in predictive chart modelsQuarterly Performance Summary & Reliable Volume Spike Trade Alerts - Newser
Transcript : Travere Therapeutics, Inc. Presents at Wells Fargo 20th Annual Healthcare Conference 2025, Sep-03-2025 01 - MarketScreener
Will Travere Therapeutics Inc. continue its uptrendMarket Activity Summary & Daily Momentum Trading Reports - Newser
Technical analysis overview for Travere Therapeutics Inc. stockShort Setup & Accurate Technical Buy Alerts - Newser
Travere Therapeutics' Strategic Momentum in Rare Disease Innovation and Commercial Execution - AInvest
Transcript : Travere Therapeutics, Inc. Presents at Cantor Global Healthcare Conference 2025, Sep-04-2025 02 - MarketScreener
Travere Therapeutics at Cantor Conference: Strategic Insights on FILSPARI By Investing.com - Investing.com Canada
Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Price Is Right But Growth Is Lacking - 富途牛牛
Why Travere Therapeutics Inc. is moving todayWeekly Trade Recap & Daily Profit Maximizing Trade Tips - Newser
Travere Therapeutics Inc. stock prediction for this weekPortfolio Growth Summary & Community Supported Trade Ideas - Newser
Can Travere Therapeutics Inc. be the next market leaderWeekly Trade Analysis & Capital Efficient Trade Techniques - خودرو بانک
Is Travere Therapeutics Inc.’s growth already priced inExit Point & AI Forecast for Swing Trade Picks - خودرو بانک
Will Travere Therapeutics Inc. outperform small cap indexes2025 Geopolitical Influence & Safe Entry Zone Identification - خودرو بانک
How to interpret RSI for Travere Therapeutics Inc. stockMarket Trend Review & AI Driven Stock Reports - Newser
Travere Therapeutics shares rise 4.74% intraday after presenting positive long-term data for pegtibatinase at the International Congress of Inborn Errors of Metabolism. - AInvest
Travere Therapeutics Presents Abstracts at the 15th International Congress of Inborn Errors of Metabolism - Business Wire
Should you hold or exit Travere Therapeutics Inc. now2025 Market Trends & Growth Focused Stock Pick Reports - Newser
Is Travere Therapeutics Inc. stock ready for a breakoutJuly 2025 Review & Expert Approved Momentum Ideas - Newser
Earnings visualization tools for Travere Therapeutics Inc.2025 Stock Rankings & Expert Approved Momentum Ideas - Newser
Statistical indicators supporting Travere Therapeutics Inc.’s strength2025 Buyback Activity & Target Return Focused Picks - Newser
Travere Therapeutics: Strategic Positioning in Renal Disease with Near-Term Catalysts and Valuation Potential - AInvest
Nephrotic Syndrome Pipeline Analysis, 2025 by DelveInsight | GlaxoSmithKline, Goldfinch Bio, Inc., Travere Therapeutics, Inc., Aurinia Pharmaceuticals, Bristol-Myers Squibb, ChemoCentryx, SynAct Pharm - Barchart.com
Transcript : Travere Therapeutics, Inc. Presents at Citi's Biopharma Back to School Conference, Sep-02-2025 03 - MarketScreener
Benchmark Reaffirms Buy Rating on Ligand with Raised PT to $175. - AInvest
Risk vs reward if holding onto Travere Therapeutics Inc.Trend Reversal & Consistent Growth Stock Picks - Newser
Is Travere Therapeutics Inc. reversing from oversold territoryJuly 2025 Opening Moves & Consistent Profit Trade Alerts - Newser
Is now the right time to enter Travere Therapeutics Inc.July 2025 Spike Watch & Detailed Earnings Play Alerts - خودرو بانک
How to monitor Travere Therapeutics Inc. with trend dashboardsChart Signals & High Accuracy Swing Trade Signals - Newser
Pullback Watch: Does Travere Therapeutics Inc. have pricing powerJuly 2025 Weekly Recap & Risk Controlled Swing Alerts - خودرو بانک
Travere Therapeutics Inc (TVTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.40%
자본화:
|
볼륨(24시간):